Dapagliflozin met primary endpoint in DELIVER Phase III trial
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Key senior hire will partner with Allison Ceraso, President and CCO, bolstering agency leadership amongst continued network momentum
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
The partners also aim to expand their work to Latin America for the first time
With close to 2,800 highly skilled employees, GITC is now one of the largest technology centres across the Life Sciences industry in the country
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
Subscribe To Our Newsletter & Stay Updated